TABLE 2.
Pharmacokinetic parameters of fosfomycin in plasma on study days 1 and 5 after two oral dosing regimens
| Study day and dosing regimena (n) | Mean ± SD |
|||||
|---|---|---|---|---|---|---|
| Cmax (μg/ml) | Tmax (h) | AUCb (μg · h/ml) | V/F (liters) | CL/F (liters/h) | t1/2 (h) | |
| Day 1 | ||||||
| QOD (18) | 23.8 ± 7.5 | 2.0 ± 0.5 | 148.8 ± 35.4 | 172 ± 70.5 | 21.6 ± 6.8 | 5.6 ± 1.5 |
| QD (18) | 23.5 ± 6.6 | 2.1 ± 0.6 | 149.8 ± 67.3 | 138.6 ± 57.4 | 22.2 ± 5.9 | 4.4 ± 1.3 |
| Day 5 | ||||||
| QOD (18) | 24.4 ± 6.2 | 2.2 ± 0.7 | 151.6 ± 35.6 | 141 ± 67.9 | 21.4 ± 8.0 | 4.5 ± 1.1 |
| QD (18) | 23.8 ± 5.6 | 2.0 ± 0.4 | 156.6 ± 42.5 | 147 ± 67.6 | 20.4 ± 5.3 | 5.0 ± 1.7 |
a
QOD, every other day; QD, every day.
b
AUC0–∞ on study day 1 and AUC0–24 on study day 5.